TARGETING DRUG TO HIV SANCTUARY IN LYMPHATICS

将药物靶向淋巴中的艾滋病毒避难所

• 批准号: 8172751
• 负责人: RODNEY J.Y. HO
• 金额: $ 31.02万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-05-01 至 2011-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8172751
• 关键词: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Antiviral Therapy; Blood; Brain; Cells; Computer Retrieval of Information on Scientific Projects Database; Data; Deposition; Disease Progression; Drug Delivery Systems; Drug Exposure; Funding; Grant; HIV; Institution; Lead; Lymphatic; Lymphoid; Lymphoid Tissue; Neuraxis; Nose; Pharmaceutical Preparations; Research; Research Personnel; Residual state; Resources; Source; Technology; Tissues; United States National Institutes of Health; Viral; Virus; improved; programs; viral resistance

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The existing HAART (highly active antiviral therapy) is effective in reducing HIV in blood to undetectable levels, the virus rebound after cessation of drug or harboring resistance virus leads to progression to AIDS. Current data indicate that residual virus in key tissues, mainly lymphoid and brain, lead to HIV disease progression. The objective of this program has been to improve localization of anti-HIV drugs to lymphoid tissues and cells so that residual virus will be eliminated from these tissues. This program plans to develop a drug delivery system that provides maximum drug exposure and viral suppression in the brain and other tissues of the central nervous system. Instead of depositing drugs in nasal cells, this technology deposits drugs in olfactory cells and provides direct access to the brain and CNS, thereby improving the efficiency of CNS delivery.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目及 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 现有的HAART（高效抗病毒疗法）可有效将血液中的HIV降低至不可检测的水平，停药后病毒反弹或携带耐药病毒导致进展为艾滋病。 目前的数据表明，关键组织（主要是淋巴组织和大脑）中残留的病毒会导致艾滋病毒疾病进展。 该计划的目标是改善抗艾滋病毒药物在淋巴组织和细胞中的定位，从而消除这些组织中残留的病毒。 该项目计划开发一种药物输送系统，在大脑和中枢神经系统的其他组织中提供最大的药物暴露和病毒抑制。 该技术不是将药物沉积在鼻细胞中，而是将药物沉积在嗅觉细胞中，并直接进入大脑和中枢神经系统，从而提高中枢神经系统输送的效率。